Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PDAT4 > 20 - Immunizations > Flashcards

20 - Immunizations Flashcards

1
Q

Which Vaccines have

BOTH
Live & Inactivated Agents

A

Influenza

POLIOmyelitis

Typhoid

Measles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which LIVE VACCINE requires a booster?

A

MMR
Needs a booster

Live Attenuated Vaccines
can replicate inside recipient –> logarithmic growth of Ag’s
typically LIFELONG immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  • *Which INACTIVATED VACCINES**
  • *do NOT require REPEATED VAX + BOOSTERS**?
A

HEP B + *Inactivated* POLIO

In INACTIVATED VACCINES:
such as Tdap / Rabies / Typhoid
they require repeated vaccination + boosters to maintain HIGH AB levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Determinants of IMMUNOGENECITY
In VACCINES

A

Chemical + Physical States
of the Ag

  • *Characteristics of INDIVIDUAL**
  • *Genetics / Physical Condition**

HOW antigen is PRESENTED
ROUTE / DOSE
TIMING of dose / ADJUVANTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

T-Lymphocyte-INdependent Immune Response
Determinants of ImmunoGenicity

A

no immunologic memory

can NOT be boosted with REPEAT injections

  • POOR immunogenicity in:*
  • *Infants / Young Children**

Can be OVERCOME by

  • *LINKAGE to CARRIER PROTEIN**
  • *Conjugated Hib / pneumococcal / meningocccal**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

T-Lymphocyte-Dependent Immune Response
Determinants of ImmunoGenicity

A

IDEAL RESPONSE

Induces:
Immunologic MEMORY

Boosts effects with REPEAT ADMIN

Provides immunogenicity to:
ALL AGE GROUPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What determines the BREADTH of an immune response?

Determinants of Immunogenicity

A

ROUTE of administration

IM & SC routes confer:
a predominantly systemic IgG response

  • *Oral** or Nasal produces:
  • *local IgA** & some systemic IgG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What determines the EXTENT of an immune response?

Determinants of Immunogenicity

A

AMOUNT of ANTIGEN delivered

Dose-Response relationship
that reaches a certain plateau

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Temporal Course of an IMMUNE RESPONSE

Initial Response

A

Protective Immune Response ~2 weeks

Circulating Antibodies appear in 7-10 days
low affinity IgM FIRST (imMediate) –> HIGH affinity IgG
IgG AB’s –> neutralize / precipitate / fix complement

  • *Titer PEAK = 2-6 weeks**
  • then begins to decrease*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Temporal Course of an IMMUNE RESPONSE

SECONDARY Response

A

“Booster”

4-5 days
vs 7-10 days for first response

HEIGHTENED Humoral or CELL-Mediated RESPONSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the ASSAY OF CHOICE
when measuring VAX Immune Response?

A
  • *OPSONOPHAGOCYTIC ACTIVITY**
  • ideally would be measuring CELL-MEDIATED immunity*

Appearance & Concentration of Serum Antibodies

Measures only the HUMORAL response = B-cell
failure can occur due to loss of circulation AB’s over time

absence of AB does NOT mean lack of protection

but also mere presence of AB does NOT mean immunity
need a SPECIFIC CONCENTRATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vaccine Development

A

Attenuation = reduced effect / virulence
achieved by serial passage in tissue celll culture lines
but still maintaining immunogenecity

Inactivated Vaccines
developed in bacteria following
concentration / purification / inactivation

NEWER vaccines are developed by:
Recombinant techniques / LIVE vectors / MICROencapsulation into polymers (sustained release)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Where should we look for
IMMUNIZATION RECOMMENDATIONS?

A
  • *ACIP**
  • *A**dvisory Committee on Immunization Practices

updated ANNUALLY

Decition to admin the vacicine involves:
Risk of Disease
+
Benefit & Risk of Vaccine

Benefit + Risk Balance may change over time
need to continually assess

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Inactivated Flu Vaccine

Production / Content

A

Primarily manufactured IN EGGS
cell culture vaccine in marine darby CANINE KIDNEY cells (still egg)

Only NON-EGG form = recombinant INSECT CELL LINE

Composed of: inactivated disrupted/split flu viruses
or of purified SURFACE antigens

A Viruses H1N1 + H3N2 & 1 B strain
quadrivalent = 2 B strains, but EQUALLY EFFECTIVE

ANTIGEN DRIFT
is why we require annual changes in vaccine components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Inactivated Flu Vaccine

Administration / Indications

A

for INACTIVATED VACCINES =
BENEFIT ALWAYS OUTWEIGHS THE RISK

IntraMuscularly

High Dose = 4x Antigenic Content

given annually for:
EVERYONE > 6 months Old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Inactivated Flu Vaccine

ADR / Effectiveness

A

60% effective at preventing flu in healthy adults < 65 y/o

despite not always PREVENTING infection, still prevents:
50% of Hospitilizations
60% of pneumonias
80% of deaths

  • ADR is UNCOMMON:*
  • *3-5% report tenderness** @ inj site or low grade fever
  • preveious SEVERE allergic reaction = CONTRAINDICATED*
17
Q

LIVE Attenuated Influenza Vaccine

INDICATION / Admin

A
  • *ADULTS aged 2-49**
  • WITHOUT:*
  • *medical complications / PREGNANCY / EGG ALLERGY**
  • *close contact w/ Pregnant or Immunocompromised adults**

Quadrivalent

  • *INTRANASALLY**
  • adrs of Nasal Congestion / HA / fever / myalgia*
18
Q

Pneumococcal CONJUGATE vaccine
PCV13

A

Pneumococcal Capsular PolySaccharide
that is
COVALENTLY LINKED to PROTEIN CARRIER
this link converts a normally INdependent vaccine into….

  • *T-CELL DEPENDENT VACCINE**
  • *Dependent (PCV13)** is given FIRST

7 Valent Vaccine = Infants / young children
for INVASIVE DISEASE = bloodstream / meningitis

13 Valent Vaccine = 2010

19
Q

Pneumococcal CONJUGATE vaccine
PCV13

RECOMMENDATIONS / INDICATIONS

A

4 Dose series: 2-4-6 months of age
booster @ 12-15 months

ACIP Recommends that:
ALL ADULTS > 65 y/o get PCV13 –> PPPSV23 after 8weeks

Also recommended for:
Adults >50 y/o with:
Immunocompromised
Renal Failure / Asplenia / CSF leak / Cochlear Implants

adr is mostly fever

20
Q

Pneumococcal POLYSACCHARIDE Vaccine

PPSV23

A

IN-DEPENDENT
Given 8 Weeks AFTER PCV13 (dependent)

Generally effective at preventing:

  • *INVASIVE**
  • *pneumococcal bacteremia**

IntraMuscular

21
Q

Pneumococcal POLYSACCHARIDE Vaccine
PPSV23

Indication / Admin

A

IM

  • *RE-VACCINATION after age 65**
  • if given:* before 65 or at least 5 years in between

Licensed for PERSONS 2+
primarily for adults that are @HIGH RISK from complications RESPIRATORY TRACT INFECTIONS
Essentially:
Everyone admitted to HOSPITAL
Asthma / immunocompromised / Age >65 / Smokers
cancer / Asplenia / Liver / renal disease

22
Q

Where to look for recommended
TRAVEL IMMUNIZATIONS?

A

CDC** or **WHO

Depends on geographic area & risk

23
Q

Illinois Pharmacist can administer

WHAT VACCINES @ WHAT AGE?

A

any vaccine to patients:
> 10 years old

  • EXCEPT:*
  • *HPV Vaccine > 14 y/o**
24
Q

Immunization considerations for:

IMMUNOCOMPROMISED

A

NEVER give LIVE vaccines

Inactivated Flu Vaccine:
should be AVOIDED
during INDUCTION / Consolidation CHEMO

  • *Efficacy of vaccines may be LESS**
  • -> require repeated doses

FAMILY MEMBERS
should be vaccinated to minimize exposure

25
Q

What TYPE of DISEASE does the
PCV7 / PCV13 / PPSV23
Vaccines

PROTECT AGAINST?

A

INVASIVE

97% efficacy for preventing invasive disease
pneumococcal bacteremia ​

  • not necessarily effective against:
  • non-bacteremic pneumonia**

PDAT4 (34 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions